Jade Biosciences, Inc. (JBIO) intrinsic value & 10-year financials
Jade Biosciences, Inc. (JBIO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $13.47
- Market cap
- $422.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -39.0%
- Free cash flow (FY2025)
- -$94.9M
JBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$127.4M | -$3.19 | -$94.9M | — | -79.0% |
| FY2024 | — | -$69.6M | -$2.44 | — | — | -115.7% |
| FY2023 | — | -$75.5M | -$2.87 | -$56.9M | — | -85.1% |
| FY2022 | — | -$51.5M | -$2.10 | -$39.3M | — | -47.6% |
| FY2021 | — | -$23.0M | -$0.94 | -$27.6M | — | -19.4% |
| FY2020 | — | -$9.6M | — | — | — | 113.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Jade Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Jade Biosciences, Inc. has historically struggled to out-earn its cost of capital, averaging just -69.4% ROIC.
Jade Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Jade Biosciences, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.